Monocyte subsets and their phenotypes during treatment with BCR‐ABL1 tyrosine kinase inhibitors for Philadelphia chromosome‐positive leukemia
暂无分享,去创建一个
Satoshi Takahashi | S. Kato | A. Tojo | T. Konuma | Masamichi Isobe | Eri Watanabe | N. Ohno | Koji Jimbo | Chisato Kohara | Motoko Mizukami | Etsuko Nagai | Susumu Tanoue
[1] G. Superti-Furga,et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site , 2017, Leukemia.
[2] E. Solary,et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis , 2017, Blood Cancer Journal.
[3] T. Ikezoe,et al. The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. , 2017, Leukemia research.
[4] S. Gabriel,et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.
[5] F. Fonseca,et al. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. , 2017, Clinical science.
[6] U. Olsson‐Strömberg,et al. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study. , 2016, Annals of internal medicine.
[7] J. Ben,et al. Class A1 scavenger receptors in cardiovascular diseases , 2015, British journal of pharmacology.
[8] J. Moslehi,et al. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Eljaszewicz,et al. The Role of Different Monocyte Subsets in the Pathogenesis of Atherosclerosis and Acute Coronary Syndromes , 2015, Scandinavian journal of immunology.
[10] E. Solary,et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. , 2015, Blood.
[11] P. Valent,et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.
[12] P. Libby,et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis , 2013, Nature Medicine.
[13] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[14] D. Fliser,et al. Cd14؉؉cd16؉ Monocytes Independently Predict Cardiovascular Events a Cohort Study of 951 Patients Referred for Elective Coronary Angiography , 2022 .
[15] B. Hedblad,et al. Elevated CD14++CD16− Monocytes Predict Cardiovascular Events , 2012, Circulation. Cardiovascular genetics.
[16] T. Simon,et al. Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice , 2008, Circulation.
[17] F. Tacke,et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.
[18] D. Fliser,et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. , 2011, European heart journal.